Cutting the Cost of Medicines, realistic approaches Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Cutting the Cost of Medicines, realistic approaches

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: scaram(o)uche	6/12/2007 12:58:39 PM
	of 2

Message 23615876 >> Who needs patent protection when you have batch to batch variability! << Really.... for those of us who were putting the first recombinant cell lines into flasks, and assessing post-translational modifications and homogeneity? This entire argument is silly. EVERYBODY was working to reduce heterogeneity. Reality is that the heterogeneity from a flask could be limited to heterogeneity that was also observed on molecules purified from humans, but that it could not be eliminated. FDA scientists understand this. If cell-based biologics end up being protected due to their inherent variability, it will be politicos that allow such, not FDA bench grunts. IMO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext